Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 10/29 04:24:24 pm
132.575 EUR   -1.61%
12:41pMERCK : Mammoth Biosciences Partner to Produce, Scale Up Covid-19 Test
DJ
10/28MERCK KGAA : Kepler Cheuvreux remains its Buy rating
MD
10/28MERCK : to Invest EUR20 Million in Display-Technology Production
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck KGaA Appoints New Executive Board Chair, CEO

share with twitter share with LinkedIn share with facebook
09/28/2020 | 10:06am EDT

By Giulia Petroni

 

Merck KGaA said Monday that it has appointed Belen Garijo as chair of the executive board and chief executive officer effective from May 1, 2021.

Ms. Garijo is currently vice chair of the board and deputy CEO as well as CEO of Healthcare. She will succeed Stefan Oschmann, who will leave the company as planned "to turn to other tasks," the German pharmaceuticals and chemicals company said.

Merck also said Peter Guenter will join the executive board of the company and assume responsibility of the Healthcare business sector effective from Jan. 1, 2021 at the latest.

Matthias Heinzel will also join the board and be responsible for Life Science effective from April 1, 2021 at the latest.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
ALMIRALL, S.A. -0.11% 9 Delayed Quote.-38.46%
DUPONT DE NEMOURS, INC. 3.60% 57.96 Delayed Quote.-12.91%
MERCK KGAA -1.67% 132.5 Delayed Quote.27.91%
share with twitter share with LinkedIn share with facebook
All news about MERCK KGAA
12:41pMERCK : Mammoth Biosciences Partner to Produce, Scale Up Covid-19 Test
DJ
10/28MERCK KGAA : Kepler Cheuvreux remains its Buy rating
MD
10/28MERCK : to Invest EUR20 Million in Display-Technology Production
DJ
10/27MERCK : MAVENCLAD® (cladribine tablets) is available through public drug plans f..
AQ
10/27MERCK KGAA : JP Morgan remains Neutral
MD
10/21MERCK KGAA : Morgan Stanley reaffirms its Neutral rating
MD
10/21MERCK KGAA : Bernstein reiterates its Neutral rating
MD
10/16Physiomics Wins Contracts With Existing Customers
DJ
10/15MERCK : Global Head of R&D for Healthcare to Retire
DJ
10/15Global Glycobiology Market to Rise at 14.64% between 2020 and 2027
AQ
More news
Financials
Sales 2020 17 303 M 20 195 M 20 195 M
Net income 2020 1 724 M 2 012 M 2 012 M
Net Debt 2020 10 812 M 12 619 M 12 619 M
P/E ratio 2020 32,4x
Yield 2020 0,99%
Capitalization 58 586 M 68 314 M 68 377 M
EV / Sales 2020 4,01x
EV / Sales 2021 3,72x
Nbr of Employees 57 523
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126,48 €
Last Close Price 134,75 €
Spread / Highest target 11,3%
Spread / Average Target -6,14%
Spread / Lowest Target -25,0%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA27.91%68 876
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD114.34%20 946
KYOWA KIRIN CO., LTD.3.03%13 754
BETTA PHARMACEUTICALS CO., LTD.69.71%6 490
YUHAN CORPORATION29.39%3 340
RECIPHARM AB (PUBL)9.93%1 645